部分响应基于sintilimab的多式疗法在一个耐火的初级中枢乳腺黄囊瘤:一个案例报告
Yibo Sun1, Xue Li1, Miaomiao Yang1
1Radiation Oncology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, CHN.
Cureus
|November 14, 2025
概括
主要的中原黄囊瘤 (PMYST) 是罕见的和积极的. 基于sintilimab的化疗免疫疗法在治疗耐火PMYST方面显示出潜力,为这种具有挑战性的癌症提供了一种新的策略.
科学领域:
- 在瘤学瘤学.
- 医学研究 医学研究
背景情况:
- 主要的中原黄囊瘤 (PMYST) 是一种极其罕见且具有攻击性的生殖细胞恶性瘤.
- 患有PMYST的患者往往面临着不良预后和有限的治疗选择.
研究的目的:
- 报告一种耐火PMYST的情况.
- 评估基于sintilimab的化疗免疫疗法在患有PMYST晚期的患者中的疗效.
主要方法:
- 一名55岁的男性患有较大的前腹中质量和高的α-fetoprotein (AFP) 被诊断出患有PMYST.
- 最初的治疗包括埃托波西德-西斯普拉丁化疗和放射治疗,随后在疾病进展后进行基于sintilimab的化疗免疫治疗.
主要成果:
- 患者最初对化疗或放射治疗有反应,但经历了疾病进展.
- 基于sintilimab的化学免疫疗法的四个周期导致了部分反应.
- 在最近的随访中观察到持续的临床稳定性和疾病控制.
结论:
- 以PD-1抑制剂为基础的组合疗法,如sintilimab,在耐火的中原黄囊瘤中显示出潜在的疗效.
- 这种方法可能为管理这种具有挑战性的恶性瘤提供了一种新的治疗策略.
相关概念视频
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K


